TIM-4 Regulates Allergic Airway Inflammation and Mast Cell Activation by Binding to CD300b
TIM-4 contributes significantly to the effector phase of allergic airway inflammation. TIM-4 may serve as a therapeutic target and sTIM-4 may have the potential to be used as surrogate marker in asthma.
Authors
- Jiro Kitaura (ORCID: https://orcid.org/0000-0002-5083-8368)
- Kumi Izawa (ORCID: https://orcid.org/0000-0003-4746-7225)
- Sachiko Miyake (ORCID: https://orcid.org/0000-0001-6349-2936)
- Hisaya Akiba (ORCID: https://orcid.org/0000-0002-1565-1098)
- Fumitaka Kamachi (ORCID: https://orcid.org/0000-0002-1244-9329)
- Chiharu Nishiyama (ORCID: https://orcid.org/0000-0002-4082-9097)
- Sonoko Harada (ORCID: https://orcid.org/0000-0002-3857-2624)
- Yuki Tanabe (ORCID: https://orcid.org/0000-0003-1463-2749)
- Jun Ito (ORCID: https://orcid.org/0000-0002-8883-2623)
- Norihiro Harada (ORCID: https://orcid.org/0000-0002-0962-5731)
- François Niyonsaba (ORCID: https://orcid.org/0000-0002-0588-8315)
- Nobuhiro Nakano (ORCID: https://orcid.org/0000-0002-5317-5950)
- Kazuhisa Takahashi (ORCID: https://orcid.org/0000-0001-5749-4118)
- Fumihiko Makino
- Yoshiyuki Abe (ORCID: https://orcid.org/0000-0002-1014-2868)
- Ko Okumura
Institutions
- Tokyo University of Science (JP)
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-10-31
- DOI
- https://doi.org/10.2147/jaa.s550326
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Research Council
- Japan Society for the Promotion of Science